Abirapro 250 mg tablets (Abiraterone acetate) | zytiga cost in India

Usage Of Abirapro

Abirapro 250mg is an inhibitor of CYP17 which is used to treats the patients with metastatic castration-resistant prostate cancer, The patient have received earlier chemotherapy with docetaxel combination with prednisone and in failure of androgen deprivation treatment. The patient clinically not used for chemotherapy with prednisone or prednisolone will preferred treatment with metastatic CRPC in adult men.

Dosage & Administration

• Prescribed dose of Abirapro 250mg tablets is 1,000 mg, Abirapro 250mg given 4 dose orally once in a day (OD).
• Abirapro tablets in Combination with prednisone 5 mg administered orally twice daily.
• Abirapro Tablets administrated on an empty stomach.
• No food should be consumed for at least 2 hours before and at least 1 hour after the dose of ABIRAPRO Tablets is taken.
• Abirapro should be swallowed whole with water.
• Do not crush or chew the tablets.

Abirapro Describe

Abirapro 250mg is a type of classification belongs to antineoplastics and it contain active ingredients of Abiraterone acetate. Which is an antiandrogen medication is indicated for the treatment of prostate cancer which spread to other parts of the body. Abirapro 250mg tablet is also used along with prednisone, a steroid. In clinical trials Abirapro is used for prostate cancer and advanced breast cancer.

Pharmacology

Absorption
Poorly absorbed and hydrolysis by esterases. Zytiga drug is a salt form, is a prodrug and have higher oral bioavailability. Time to maximum serum concentration is 1.5 – 4 hours. Food and high fat meals increases absorption.

Distribution
Protein bound to alpha – 1- acid glycoprotein and albumin is >99%

Metabolism
By hydrolyzed Abiraterone Acetate is converted into active metabolite Abiraterone through esterases. metabolized in CYP3A4 and SULT2A1

Elimination
Excreted through feces (88%) and urine (5%). Terminal half life is 5-14hours.

Mechanism Of Action

A type of steroidal enzyme inhibitor CYP17A1 (17 alpha-hydroxylase/C17,20 lyase) is known as abirateron acetate which is an orally active and It interefere with CYP17A1 in a selective and invariable manner through covalent binding mechanism. An enzyme CYP17A1 which catalyzes the biosynthesis of androgen and is highly expressed in testicular, adrenal, and prostatic tumor tissue. Particularily , abiraterone prevents the conversion of 17-hydroxyprognenolone to dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 to reduce serum levels of testosterone and other androgens.

Drug Interaction

→ Effects of Abiraterone (Abirapro 250mg) on drug metabolizing enzymes
Abiraterone is a hepatic drug-metabolizing inhibitor CYP2D6, when substrates (dextromethorphan) of it is co administrated with Abiraterone will increases the Cmax and AUC dextromethorphan.
→ Drugs that inhibits or induce CYP3A4
Abiraterone interaction with strong CYP3A4inhibitors or inducers, the pharmacokinetics of Abiraterone is not evaluated properily, so avoid or use with caution while abiterone therapy.

Abiraterone Side Effects

Patients taking Abiraterone acetate have following side effects are common in >30% occurring
• Retention of fluid
• Triglycerides increased
• Increased liver enzyme
Less common side effects of Abiraterone 10-29% occurring:
• Joint discomfort
• Hypokalemia
• Swelling of hands/ feets
• Myalgia
• Hypophosphatemia
• UTI